FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*						2. Issuer Name and Ticker or Trading Symbol HARROW HEALTH, INC. [HROW]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
BAUM MARK L						In the William in the Control of the William in the								X Direc		tor	10	10% Owner	
(Last)	(F	irst) (Date of Earliest Transaction (Month/Day/Year)									X	Office belov	er (give title v)		Other (specify below)			
C/O HARROW HEALTH, INC.					12/2	12/22/2022								Chief Executive Officer					
102 WOODMONT BLVD, SUITE 610																			
						If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) NASHV	ILLE T	NT 2											ine) X	-/					
NASHV.	ILLE I	IN 3	37205											Form filed by More than One Reporting					
(City)	(S	tate) (2	Zip)												Perso	on			
		Toblo	I Na	n Dorive	tivo (200111	rition	Λος		ı Die	posed of	E	lonofic	الما	O.440				
			1 - NC					ACC	<u>. </u>	אט, גו	•	<u> </u>						_	
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/					Execution Date,		,				s Acquired (A) of f (D) (Instr. 3, 4		and 5) Securi			6. Ownersh Form: Direc (D) or Indirec (I) (Instr. 4)	t c	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) o	Price		Repor Transa (Instr.	ted action(s) 3 and 4)		(1	(Instr. 4)
Common Stock 12/22/20					022				P		25,000	A	\$13	39 ⁽¹⁾	1,432,141		D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
(e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		if any	eemed tion Date, h/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exer Expiration D (Month/Day/		ate	7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		Der	rice of ivative urity tr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owner Form: Direct or Indi (I) (Ins	(D) rect	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amount or Number of Shares						

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$13.34 to \$13.42, inclusive. The reporting person undertakes to provide to Harrow Health, Inc. ("Harrow"), any security holder of Harrow, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

/s/ Mark L. Baum

12/23/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.